Information Provided By: 
Fly News Breaks for March 16, 2015
STJ
Mar 16, 2015 | 08:05 EDT
BMO Capital believes that data on St. Jude's CardioMEMS supports adoption of the product. The firm believes that the data shows that the product not only reduces heart failure, but also lowers re-hospitalization rates and patient mortality. The firm thinks the company's 2015 revenue guidance for the product is beginning to appear conservative. BMO keeps an Outperform rating on the shares.
News For STJ From the Last 2 Days
There are no results for your query STJ
